Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rene Hollestein"'
Autor:
Jaap J. Zwaginga, Bronno van der Holt, Peter A. te Boekhorst, Bart J. Biemond, Mark-David Levin, René van der Griend, Anneke Brand, Sonja Zweegman, Hans F.M. Pruijt, Vera M.J. Novotny, Art Vreugdenhil, Marco R. de Groot, Okke de Weerdt, Elisabeth C.M. van Pampus, Tanja M. van Maanen-Lamme, Shulamiet Wittebol, Martin R. Schipperus, Matthijs H. Silbermann, Peter C. Huijgens, Marleen Luten, Rene Hollestein, Jan A.C. Brakenhoff, Jolanda G. Schrama, Fransje A.A. Valster, Gerjo A. Velders, Harry R. Koene
Publikováno v:
Haematologica, Vol 100, Iss 3 (2015)
Externí odkaz:
https://doaj.org/article/aa9c02bce86b43a7ad184444996b6a14
Autor:
Okke de Weerdt, Dimitri Breems, Bob Löwenberg, Mark-David Levin, Edo Vellenga, August Ferrant, Georg Stussi, Mels Hoogendoorn, Harry C. Schouten, Kees van Montfort, Rene Hollestein, Constantijn J.M. Halkes, Georgine E. de Greef, Yvette van Norden, Johan Maertens, Marinus van Marwijk Kooij, Gregor Verhoef, Mojca Jongen-Lavrencic, Bart J. Biemond, Gert J. Ossenkoppele, Pierre W. Wijermans, Arjan A. van de Loosdrecht, Jakob Passweg, Carlos Graux, Thomas Pabst
Publikováno v:
Blood, 120(24), 4706-4711
Blood, 120(24), 4706-4711. AMER SOC HEMATOLOGY
Blood, 120(24), 4706-4711. The American Society of Hematology
Blood
Blood, 120(24), 4706-4711. American Society of Hematology
Ossenkoppele, G J, Stussi, G, Maertens, J, van Montfort, K, Biemond, B J, Breems, D, Ferrant, A, Graux, C, de Greef, G E, Halkes, C J M, Hoogendoorn, M, Hollestein, R M, Jongen-Lavrencic, M, Levin, M D, van de Loosdrecht, A A, van Marwijk-Kooij, M, van Norden, Y, Pabst, T, Schouten, H C, Vellenga, E, Verhoef, G E G, de Weerdt, O, Wijermans, P, Passweg, J R & Lowenberg, B 2012, ' Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK) ', Blood, vol. 120, no. 24, pp. 4706-4711 . https://doi.org/10.1182/blood-2012-04-420596
Blood, Vol. 120, no. 24, p. 4706-4711 (2012)
Blood, 120(24), 4706-4711. AMER SOC HEMATOLOGY
Blood, 120(24), 4706-4711. The American Society of Hematology
Blood
Blood, 120(24), 4706-4711. American Society of Hematology
Ossenkoppele, G J, Stussi, G, Maertens, J, van Montfort, K, Biemond, B J, Breems, D, Ferrant, A, Graux, C, de Greef, G E, Halkes, C J M, Hoogendoorn, M, Hollestein, R M, Jongen-Lavrencic, M, Levin, M D, van de Loosdrecht, A A, van Marwijk-Kooij, M, van Norden, Y, Pabst, T, Schouten, H C, Vellenga, E, Verhoef, G E G, de Weerdt, O, Wijermans, P, Passweg, J R & Lowenberg, B 2012, ' Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK) ', Blood, vol. 120, no. 24, pp. 4706-4711 . https://doi.org/10.1182/blood-2012-04-420596
Blood, Vol. 120, no. 24, p. 4706-4711 (2012)
An urgent need for new treatment modalities is emerging in elderly patients with acute myeloid leukemia (AML). We hypothesized that targeting VEGF might furnish an effective treatment modality in this population. Elderly patients with AML were random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1a3187e603c849217223f25d74c8bad
http://hdl.handle.net/1887/98066
http://hdl.handle.net/1887/98066
Autor:
Okke de Weerdt, Marleen Luten, René van der Griend, Anneke Brand, Ronnie van der Holt, Peter A. W. te Boekhorst, Jaap Jan Zwaginga, Sonja Zweegman, Art Vreughdenhil, Elisabeth C. M. Van Pampus, Bart J. Biemond, P. C. Huijgens, Mark Levin, Harry R. Koene, Rene Hollestein, Hans Pruijt
Publikováno v:
Blood, 116(21), 1042-1042
Zwaginga, J J, van der Holt, R, Biemond, B J, Boekhorst, P A W, Levin, M, Vreughdenhil, A, Huijgens, P C, Brand, A, van der Griend, R, Luten, M, Pruijt, H, de Weerdt, O, van Pampus, E, Zweegman, S, Hollestein, R & Koene, H R 2010, ' Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients: ' . < http://www.mendeley.com/research/interim-analysis-dutch-hovon-multicenter-randomized-open-label-phase-ii-trial-3-rituximab-dosing-sch >
Zwaginga, J J, van der Holt, R, Biemond, B J, Boekhorst, P A W, Levin, M, Vreughdenhil, A, Huijgens, P C, Brand, A, van der Griend, R, Luten, M, Pruijt, H, de Weerdt, O, van Pampus, E, Zweegman, S, Hollestein, R & Koene, H R 2010, ' Interim Analysis on a Dutch HOVON Multicenter Randomized Open Label Phase II Trial on 3 Rituximab Dosing Schemes In Chronic ITP Patients: ' . < http://www.mendeley.com/research/interim-analysis-dutch-hovon-multicenter-randomized-open-label-phase-ii-trial-3-rituximab-dosing-sch >
Abstract 2514 The overall short term effectivity of Rituximab in the treatment of ITP is reported to be around 50%. In most studies the traditional CD20 dosing scheme of 4 weekly interspaced 375 mg/m2 doses is used although other single-arm studies s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91342096607e19be0be834be6df27b24
http://hdl.handle.net/1887/118378
http://hdl.handle.net/1887/118378